REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-15. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Light-emitting diodes (LEDs) can be manufactured to emit radiation in the ultraviolet range. In 2019, following significant advances over the preceding five years, UVA LEDs of 365 nm and longer wavelength were available, with efficiencies of 50% at 1.0 W output. Currently, the most common types of UV LEDs are in 395 nm and 365 nm wavelengths, both of which are in the UVA spectrum. The rated wavelength is the peak wavelength that the LEDs put out, but both higher and lower wavelengths are present. The cheaper and more common 395 nm UV LEDs are much closer to the visible spectrum, and give off a purple color. Other UV LEDs deeper into the spectrum do not emit as much visible light. LEDs are used for applications such as UV curing applications, charging glow-in-the-dark objects such as paintings or toys, and lights for detecting counterfeit money and bodily fluids. UV LEDs are also used in digital print applications and inert UV curing environments. As technological advances beginning in the early 2000s have improved their output and efficiency, they have become increasingly viable alternatives to more traditional UV lamps for use in UV curing applications, and the development of new UV LED curing systems for higher-intensity applications is a major subject of research in the field of UV curing technology. UVC LEDs are developing rapidly, but may require testing to verify effective disinfection. Citations for large-area disinfection are for non-LED UV sources known as germicidal lamps.
Burial, also known as interment or inhumation, is a method of final disposition whereby a dead body is placed into the ground or in a structure such as a mausoleum, sometimes with objects. This is usually accomplished by excavating a pit or trench, placing the deceased and objects in it, and covering it over. A funeral is a ceremony that accompanies the final disposition. Evidence suggests that some archaic and early modern humans buried their dead. Burial is often seen as indicating respect for the dead. It has been used to prevent the odor of decay, to give family members closure and prevent them from witnessing the decomposition of their loved ones, and in many cultures it has been seen as a necessary step for the deceased to enter the afterlife or to give back to the cycle of life. Methods of burial may be heavily ritualized and can include natural burial (sometimes called "green burial"); embalming or mummification; and the use of containers for the dead, such as shrouds, coffins, grave liners, and burial vaults, all of which can slow decomposition of the body. Sometimes objects or grave goods are buried with the body, which may be dressed in fancy or ceremonial garb. Depending on the culture, the manner in which the body is positioned may have great significance. The location of the burial may be determined by taking into account concerns surrounding health and sanitation, religious concerns, and cultural practices.
Fasting blood sugar (glucose) level of: 110 to 125 mg/dL (6.1 mmol/L to 6.9 mmol/L) – WHO criteria 100 to 125 mg/dL (5.6 mmol/L to 6.9 mmol/L) – ADA criteria Glucose tolerance test: blood sugar level of 140 to 199 mg/dL (7.8 to 11.0 mM) 2 hours after ingesting a standardized 75 gram glucose solution (WHO and ADA criteria) Glycated hemoglobin (HbA1c) between 5.7 and 6.4 percent, i.e., 38.9 and 46.4 mmol/mol Levels above these limits would justify a diagnosis for diabetes.
== C == C-T scan (computed tomography scan) – cachexia – Canadian Foundation for AIDS Research – candida – candidiasis – carcinogen – CAT scan – CCR5 – CD4 (T4) or CD4 + cells – CDC National Prevention Information Network (CDC-NPIN) – cell lines – cell-mediated immunity (CMI) – cellular immunity – Centers for Disease Control and Prevention (CDC) – Centers for Medicare and Medicaid Services (CMS) – central nervous system – cerebrum – cerebrospinal fluid (CSF) – cervical cancer – cervical dysplasia – cervical intraepithelial neoplasia (CIN1, CIN2, CIN3) – cervix – chancroid – chemokines – chemoprophylaxis – chemotherapy – Chlamydia – chronic idiopathic demyelinating polyneuropathy (CIPD) – circumoral paresthesia – clade – clinical endpoint – clinical latency – clinical practice guidelines – clinical trial – clinicaltrials.gov – cloning – CMS – CMV – CNS – co-receptors – coccidioidomycosis – codon – cofactors – cognitive impairment – cohort – colitis – combination therapy – community planning – Community Programs for Clinical Research on AIDS (CPCRA) – community-based clinical trial (CBCT) – community-based organization (CBO) – compassionate use – complement – complement cascade – complementary and alternative therapy – complete blood count (CBC) – computed tomography scan (C-T scan) – concomitant drugs – condyloma – condyloma acuminatum – contagious – contraindication – controlled trials – core – core protein – correlates of immunity/correlates of protection – creatinine – cross-resistance – cryotherapy – cryptococcal meningitis – cryptococcosis – Cryptococcus neoformans – cryptosporidiosis – Cryptosporidium – CSF – CTL – cutaneous – CXCR4 – cytokines – cytomegalovirus (CMV) – Cytomegalovirus retinitis – cytopenia – cytotoxic – cytotoxic T lymphocyte (CTL)
Sources: en.wikipedia.org
Johnson meets with Soviet Premier Alexei Kosygin in Glassboro, New Jersey for a three-day summit. July 1: Beginning of the War of Attrition. July 6: The Nigerian Civil War begins in response to Biafra's declaration of independence. August 8: Bangkok Declaration is established to quell the communist threat in Southeast Asia. This creates ASEAN. October 8: Che Guevara is captured in Bolivia by U.S. trained Bolivian rangers. October 9: Che Guevara is executed after being captured the day before. November 29: Robert McNamara announces that he will resign as U.S. Secretary of Defense to become President of the World Bank.
=== Hoyle–Wickramasinghe model of panspermia === Throughout his career, Wickramasinghe, along with his collaborator Fred Hoyle, has advanced the panspermia hypothesis, that proposes that life on Earth is, at least in part, of extraterrestrial origin. The Hoyle–Wickramasinghe model of panspermia include the assumptions that dormant viruses and desiccated DNA and RNA can survive unprotected in space; that small bodies such as asteroids and comets can protect the "seeds of life", including DNA and RNA, living, fossilized, or dormant life, cellular or non-cellular; and that the collisions of asteroids, comets, and moons have the potential to spread these "seeds of life" throughout an individual star system and then onward to others. The most contentious issue around the Hoyle–Wickramasinghe model of the panspermia hypothesis is the corollary of their first two propositions that viruses and bacteria continue to enter the Earth's atmosphere from space, and are hence responsible for many major epidemics throughout history. Towards the end of their collaboration, Wickramasinghe and Hoyle hypothesised that abiogenesis occurred close to the Galactic Center before panspermia carried life throughout the Milky Way, and stated a belief that such a process could occur in many galaxies throughout the Universe.
Emma Schymanski (née Craven) is an Australian chemist known for her work identifying unknown organic compounds, particularly pollutants, and is an advocate for open science. She is currently a Professor of Cheminformatics at the University of Luxembourg.
== 3D structure == The overall fold of Rieske proteins, comprising two subdomains, is dominated by antiparallel β-structure and contains variable numbers of α-helices. The smaller "cluster-binding" subdomains in mitochondrial and chloroplast proteins are virtually identical, whereas the large subdomains are substantially different in spite of a common folding topology. The [Fe2S2] cluster-binding subdomains have the topology of an incomplete antiparallel β-barrel. One iron atom of the Rieske [Fe2S2] cluster in the domain is coordinated by two cysteine residues and the other is coordinated by two histidine residues through the Nδ atoms. The ligands coordinating the cluster originate from two loops; each loop contributes one Cys and one His.
==== Analysis and appreciation ==== Birzer, Bradley J. Cultural Repercussions: An In-Depth Examination of the Words, Ideas and Professional Life of Neil Peart, Man of Letters. Wordfire Press, 2015. ISBN 1614753547. Bowman, Durrell and Berti, Jim. Rush and Philosophy: The Heart and Mind United. Open Court Press, 2011. ISBN 978-0812697162. Bowman, Durrell. Experiencing Rush: A Listener's Companion. Rowman & Littlefield Publishers, 2014. ISBN 1442231300. Freedman, Robert. Rush: Life, Liberty, and the Pursuit of Excellence. Algora Pub, 2014. ISBN 1628940840. McDonald, Chris. Rush, Rock Music, and the Middle Class: Dreaming in Middletown. Indiana University Press, 2009. ISBN 0-253-22149-8. Mobley, Max. Rush FAQ: All That's Left to Know About Rock's Greatest Power Trio. Backbeat Books, 2014. ISBN 1617134511. Popoff, Martin. Rush: Album by Album. Voyageur Press, 2017. ISBN 978-0760352205. Price, Carol S. and Robert M. Price. Mystic Rhythms: The Philosophical Vision of Rush. Wildside Press, 1999. ISBN 1-58715-102-2. Roberto, Leonard. A Simple Kind Mirror: The Lyrical Vision of Rush. Iuniverse Star, 2000. ISBN 0595213626. Telleria, Robert. Rush Tribute: Merely Players. Quarry Press, 2002. ISBN 1-55082-271-3.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.